Search alternatives:
largest decrease » marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
largest decrease » marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
-
5481
Minigene assay of rare missense VUS in exon 10.
Published 2025“…<p><b>(a)</b> Position of variants that were tested by minigene assay. …”
-
5482
Isolation and characterization of the <i>clr4–1</i> mutant strain.
Published 2025“…Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using a one-way ANOVA followed by Dunnett’s multiple comparison test, with WT as the reference sample (*<i>p</i> < 0.05 and **<i>p</i> < 0.01; N.S.: not significant).…”
-
5483
Data Sheet 1_Comparison of the efficacy and safety of different growth factors in the treatment of diabetic foot ulcers: an updated network meta-analysis.docx
Published 2025“…Objective<p>This study aimed to evaluate the efficacy and safety of different growth factors (GFs) in the treatment of diabetic foot ulcers (DFUs) through a network meta-analysis.</p>Methods<p>A systematic search was conducted in PubMed, Embase, The Cochrane Library, and Web of Science to identify randomized controlled trials (RCTs) comparing GFs with standard of care (SOC) or comparing different GFs for the treatment of DFU. …”
-
5484
Figure 2 from Loss of Sorting Nexin 10 Accelerates KRAS-Induced Pancreatic Tumorigenesis
Published 2025“…Statistically significant differences *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; and #, <i>P</i> < 0.001 are represented as mean ± SEM. MW, molecular weight; OD, optical density; PI-A, propidium iodide area.…”
-
5485
Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx
Published 2025“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
-
5486
Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx
Published 2025“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
-
5487
Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx
Published 2025“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
-
5488
Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx
Published 2025“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
-
5489
Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx
Published 2025“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
-
5490
<b>Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow up: Relation to Dysglycemia</b>
Published 2025“…<p dir="ltr">Type 1 diabetes has detrimental effects in white matter microstructure. In a longitudinal study, we investigated if these reported findings change as children grow and enter puberty.…”
-
5491
Table 1_Effect of cholecalciferol on immune and vascular function in non-diabetic chronic kidney disease.docx
Published 2025“…</p>Results<p>In total, 62 subjects were studied. The mean age was 44 ± 12 years with 58% men. TH1 cells decreased from 17% (9%, 27%) to 11% (6%, 16%) (p=0.002) and TH2 cells increased from 9% (5%, 16%) to 16% (10%, 27%) (p=0.001) after cholecalciferol treatment. …”
-
5492
Figure 5 from Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma
Published 2025“…<b>A,</b> A cartoon demonstrating the experimental setup is shown. …”
-
5493
Table 1_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx
Published 2025“…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
-
5494
<b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli...
Published 2025“…</p><p dir="ltr"><i>Conclusions:</i> In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.…”
-
5495
Table 2_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx
Published 2025“…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
-
5496
Supplementary file 1_Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis.docx
Published 2025“…Background<p>Traumatic brain injury (TBI) represents a major global health challenge. Several clinical studies have suggested that Xuebijing (XBJ)—a patented Chinese botanical drug preparation may confer neuroprotective and anti-inflammatory benefits in TBI. …”
-
5497
Baseline characteristics of the study population.
Published 2025“…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
-
5498
Patient disposition.
Published 2025“…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
-
5499
Table 1_Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.docx
Published 2025“…Participants were recruited from December 2021 to June 2022, with a follow-up period of 180 days. We evaluated humoral immune responses and their longevity by measuring the geometric mean titers (GMTs) of neutralizing antibodies against the SARS-CoV-2 virus at various time points post-boost. …”
-
5500
Factors affecting LLINs usage at household level.
Published 2025“…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”